Prescribing pattern of antipsychotics for patients with schizophrenia using the total daily dose online tool

Alsabhan, Jawza F.; Almalag, Haya M.; Aljafali, Lubna; Alnughamish, Hessa; Almutlaq, Gaida

doi:10.1016/j.jsps.2023.101837

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, clozapine, olanzapine, quetiapine, aripiprazole, and risperidone are the broadly used atypical antipsychotics and can treat both the positive and negative symptoms of psychosis. Antipsychotic prescription patterns can vary depending on the geographical region of the world, with a preference for older (and therefore less costly) molecules in developing countries, and on the use of the drug, with a preference for atypical antipsychotics in off-label settings [99][100][101][102].…”

Section: Tdm and Antipsychoticsmentioning

confidence: 99%

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Biso,

Aringhieri,

Carli

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Psychiatric disorders often require pharmacological interventions to alleviate symptoms and improve quality of life. However, achieving an optimal therapeutic outcome is challenging due to several factors, including variability in the individual response, inter-individual differences in drug metabolism, and drug interactions in polytherapy. Therapeutic drug monitoring (TDM), by measuring drug concentrations in biological samples, represents a valuable tool to address these challenges, by tailoring medication regimens to each individual. This review analyzes the current landscape of TDM in psychiatric practice, highlighting its significance in optimizing drug dosages, minimizing adverse effects, and improving therapeutic efficacy. The metabolism of psychiatric medications (i.e., mood stabilizers, antipsychotics, antidepressants) often exhibits significant inter-patient variability. TDM can help address this variability by enhancing treatment personalization, facilitating early suboptimal- or toxic-level detection, and allowing for timely interventions to prevent treatment failure or adverse effects. Furthermore, this review briefly discusses technological advancements and analytical methods supporting the implementation of TDM in psychiatric settings. These innovations enable quick and cost-effective drug concentration measurements, fostering the widespread adoption of TDM as a routine practice in psychiatric care. In conclusion, the integration of TDM in psychiatry can improve treatment outcomes by individualizing medication regimens within the so-called precision medicine.

show abstract

Section: Tdm and Antipsychoticsmentioning

confidence: 99%

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Biso,

Aringhieri,

Carli

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Polypharmacy and high-alert medications in patients with nasally placed feeding tube on admission and at hospital discharge: Multicenter cross-sectional study

Gimenes,

Freitas,

Koepp

et al. 2024

Exploratory Research in Clinical and Social Pharmacy

View full text Add to dashboard Cite

Schizophrenic patient’s preference for long-acting injectable antipsychotics in Saudi Arabia

Aljumah,

Al-Zaagi,

Almutairi

et al. 2024

JMAHS

View full text Add to dashboard Cite

Objectives: Gaining insight into patients' preferences for long-acting injectable (LAI) antipsychotics could aid in mitigating potential barriers to the utilization of LAI in patients with schizophrenia. Methodology: A cross-sectional descriptive study was conducted among schizophrenic patients in Saudi Arabia between June 2023 and October 2023. An analysis was conducted on the responses obtained from the Medication Preference Questionnaire. Results: There was a subtle trend toward favouring oral antipsychotics over LAIs. Patients on oral antipsychotics commonly favoured the following outcomes: "I don't have to worry about taking medicines" (77%), "I can get back to my favourite activity" (71%), and "I feel symptoms will not come back" (65%). Most patients favoured gluteal injections over deltoid injections for the following reasons: easier use (90%), improved symptom relief (73%), lesser side effects (73%), and reduced pain (73%). Overall, 65% of patients favoured the dose once per month as opposed to three times per month (18%) or daily (17%). The common reasons cited by patients who favoured a 1-monthly dose were "less medication-related conflict" (97%) and "dislike to taking too much medication at once (93%)." Conclusion: This study unveiled the presence of a subtle differentiation between LAI antipsychotics and oral antipsychotics in terms of their relative desirability, with a slight inclination toward an increased preference for oral medications. Patients with schizophrenia favoured the gluteal injection over the deltoid injection on account of its greater ease of use, efficacy in symptom relief, absence of adverse effects, and reduced discomfort. Furthermore, patients exhibited a greater inclination towards monthly LAI in comparison to 3-monthly LAI and oral pill antipsychotics.

show abstract

Prescribing pattern of antipsychotics for patients with schizophrenia using the total daily dose online tool

Cited by 3 publications

References 20 publications

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Polypharmacy and high-alert medications in patients with nasally placed feeding tube on admission and at hospital discharge: Multicenter cross-sectional study

Schizophrenic patient’s preference for long-acting injectable antipsychotics in Saudi Arabia

Contact Info

Product

Resources

About